Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Neogen Chemicals Ltd - 542665 - Board Meeting Outcome for Intimation Of Acquisition Of 100% Equity Shares Of Buli Chemicals India Private Limited.

 With regards to the captioned subject and in compliance with the SEBI (LODR) Regulation 2015 we wish to inform you that the Board of Directors of Neogen Chemicals Limited at its meeting held today i.e. Saturday, March 4, 2023 which commenced at 7.15 p.m. (IST) and concluded at 8.50 p.m.(IST), inter alia, considered and approved, the acquisition of 4,69,26,000 (100%) Equity Shares of a face value of Rs. 10 each, of BuLi Chemicals India Private Limited ('BuLi Chem') for an amount up to Rs. 25,00,00,000 approximately, subject to final working capital adjustments on closing date ('Acquisition'). Further, the Board of Directors of the Company has approved the draft of Share Purchase Agreement ('SPA') which was placed before them, for purchase of 100% equity shares of BuLi Chem from Livent USA Corporation and Livent Corporation ('Selling Shareholders') subject to the terms of SPA. Pursuant to the said transaction BuLi Chem will become a Wholly Owned Subsidiary of the Company.
04-03-2023
Bigul

Neogen Chemicals Ltd - 542665 - Closure of Trading Window

 This is to inform you that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and the Company's Code of Conduct for Prohibition of Insider Trading ('Insider Trading Policy'), the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives/ Connected Persons/ Legitimate Insiders of the Company from Thursday, March 2, 2023 till the end of 48 hours after the conclusion of upcoming Board Meeting to be held on Saturday, March 4, 2023.
02-03-2023
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Please find enclosed herewith the Earnings Call Transcript of the Company's Q3 9M FY23 Earnings Conference Call held on February 13, 2023.
20-02-2023
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Listing Regulations, we would like to inform you that the management of Neogen Chemicals Limited will be participating in the investor conferences to discuss Q3FY23 Results.
20-02-2023

Neogen Standalone December 2022 Net Sales at Rs 186.25 crore, up 40.42% Y-o-Y
14-02-2023
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 In compliance with Regulation 30 of the Listing Regulations, the audio recording of the earnings conference call held on Monday, February 13, 2023 for analysts and investors to discuss the Q3 & 9M FY23 results, is hosted on Company''s website at https://neogenchem.com/financial-performance/ .
13-02-2023
Bigul

Q3FY23 Quarterly Result Announced for Neogen Chemicals Ltd.

 Neogen Chemicals announced Q3FY23 results: Q3FY23 & 9MFY23: Neogen Chemicals Limited (Neogen) reported strong financial performance during the quarter and nine months ended Q3FY23. In 9MFY23, the company delivered 46% growth in revenues, 32% increase in EBITDA and 23% growth in Profit After Tax (PAT). In 9MFY23, revenues were at Rs 482.3 crore, with a growth of 46% YoY. Growth was strengthened by increased utilization of plants, driven by stable demand from key end-user industries. Efforts to expand the high-margin advanced intermediates and custom synthesis manufacturing business have begun to show positive results. EBITDA at Rs 79 crore in 9MFY23 was up 32% in spite of the ongoing inflation in certain raw materials and utilities, strong EBITDA results were achieved through favorable management of product mix. The company experienced an increase in certain costs such as employee expenses, etc., consistent with management's plan to expand the workforce across departments. The company delivered a healthy EBITDA performance mainly because it was able to pass on the significant cost increase in the prices of lithium raw materials to customers. As a result, the absolute EBITDA remained protected. Profit after tax (PAT) stood at Rs 35.7 crore during 9MFY23, higher by 23% compared to Rs 29 crore in 9MFY22. The growth in PAT reflected the operational performance, moderately affected by high depreciation associated with new capacity additions and an increase in finance costs due to elevated interest rates. Earnings per share (EPS) for 9MFY23 stood at Rs 14.29 per share (Rs 12.43 per share in 9MFY22). Commenting on the Q3 & 9MFY23 performance, Mr. Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: “We registered solid performance trajectory in Q3FY23, bolstered by 40% YoY gains in revenue with healthy profitability, where both EBITDA and PAT increased by 27% and 40% YoY respectively. Our performance has been consistent, and we are witnessing accelerated built up in our business based on strong visibility and continued positive demand environment. Our capabilities in chosen chemistries are exceptional and well appreciated by our partner customers. In-line with our focus on high value-addition, we are scaling up revenues across both advanced intermediates and custom synthesis manufacturing as reflected in better profitability trends. This was achieved despite impact of continued high inflation in some input and utility costs during the period under review Our expansion plans are ambitious, but modular in nature. Our intent is to cement our leadership position in the existing business, while garnering substantial market share in the high potential Lithium-ion battery chemicals space. All the strategic initiatives undertaken this quarter including new CAPEX announcements and forming a separate entity for battery chemicals business are steps in the right direction to gain early mover advantage, be future ready with capacities meeting demand and strengthening our technological expertise. All this will result in sustained valuecreation for our stakeholders. With this, I believe we have built a solid foundation for Neogen Chemicals to independently grow and self-sustain both its existing as well as battery chemicals businesses. I am optimistic that these advancements will enable Neogen to achieve quantum leap in its earnings and demonstrate its manufacturing excellence to customers across the globe. A favourable demand outlook and India's emergence as a favored manufacturing hub will expand the market size and draw in additional customers along the value chain.” Result PDF
13-02-2023
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Investor Presentation

 With reference to the captioned subject, please find enclosed herewith the Earnings Presentation on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022.
12-02-2023
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release- Q3 9M FY23 Unaudited Results
12-02-2023
Bigul

Neogen Chemicals Ltd - 542665 - Outcome Of Board Meeting Held On February 11, 2023

 The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31, 2022, pursuant to Regulation 33 of the Listing Regulations along with the 'Limited Review Report' thereon as submitted by the Statutory Auditors of the Company and duly reviewed and recommended by the Audit Committee.
11-02-2023
Next Page
Close

Let's Open Free Demat Account